Bluebird submits US marketing application for blood disorder gene therapy


April 24 (Reuters) - Bluebird bio BLUE.O said on Monday it has submitted a marketing application to the U.S. Food and Drug Administration for its gene therapy to treat sickle cell disease, a blood disorder.

The company said its application to the health regulator included a request for priority review.

(Reporting by Bhanvi Satija in Bengaluru; Editing by Devika Syamnath)

((; Outside U.S. +91 9873062788;))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Info icon

This data feed is not available at this time.

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.